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Abstract
Background: Both tumor-associated macrophages (TAMs) and the epithelial to mesenchymal transition (EMT) of
cancer cells play key roles in promoting tumor progression. However, whether TAMs could induce EMT in the
progression of oral squamous cell carcinoma (OSCC) remains undefined.
Results: Here we detected the expression of macrophages markers CD68 and CD163, epithelial marker E-cadherin
and mesenchymal marker vimentin in 127 OSCC patients by using semi-quantitative immunohistochemistry. CD68
and CD163 expression was not confined to the infiltrating TAMs, but also detected in cancer cells. The high
number of CD68-positive macrophages was correlated with poor overall survival. Meanwhile, the expression of
CD163 both in macrophages and in cancer cells was associated with poor overall survival and had a significant
prognostic impact in OSCC. Importantly, the expression of CD163 in cancer cells had a significant relationship with
E-cadherin and vimentin. Furthermore, the incubation of TAMs conditioned medium resulted in a fibroblast-like
appearance of cancer cells (HN4, HN6 and SCC9) together with the decreased/increased expression of E-cadherin/
vimentin, which were correlated with the enhanced ability of migration and invasion.
Conclusions: Our results indicate that TAMs could promote the EMT of cancer cells, thereby leading to the
progression of oral cancer.
Keywords: Tumor-associated macrophages, CD68, CD163, Epithelial to mesenchymal transition, Oral squamous cell
carcinoma
Background
Oral squamous cell carcinoma (OSCC), the most com-
mon cancer in the head and neck, is associated with
high metastasis and poor prognosis [1]. Despite advances
in the surgical, chemotherapy and radiotherapy treat-
ment option, the five-year survival rate has not been im-
proved significantly in the past years.
Increasing studies indicate that the tumor microenvir-
onment is important for cancer development and metasta-
sis [2–4]. It contains diverse cells including leukocytes and
fibroblasts. As one of major leukocytes, macrophages play
a critical role in carcinogenesis and tumor progression [5].
They could be divided into two subgroups, the classically
activated M1-type and the alternatively activated M2-type
[6, 7]. The macrophages present in tumors are generally
considered as tumor-associated macrophages (TAMs),
which have a M2 phenotype and express CD68 and
CD163 [7]. The high density of TAMs correlates with a
poor prognosis and influences the initiation, progression
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and metastasis of various solid tumors [4, 8]. Recent stud-
ies demonstrate that the CD68-positive macrophages and
CD163-positive macrophages correlate with histological
grade and poor prognosis [1, 9–11]. Notably, cancer
cells also express the macrophages antigen CD68 and
CD163. The macrophage-like traits of cancer cells show a
correlation to poor survival in malignant glioma, breast
cancer, colorectal cancer, and malignant melanoma [12].
However, the mechanism underlying TAMs in OSCC in-
vasiveness and metastasis has not been sufficiently ana-
lyzed. The precise role of macrophages antigen CD68 and
CD163 in OSCC progression remains poorly understood.
Currently, the epithelial to mesenchymal transition
(EMT) has been regarded to be involved in the progres-
sion of cancer. During the transition process, epithelial
cells acquire fibroblastoid properties, and become motile
and invasive. Importantly, our previous studies have found
that the EMT contributes to invasion and metastasis in
OSCC [13–15]. Recent studies demonstrate that cancer
cells undergoing EMT at the invasive front of tumor tissue
can establish a suitable microenvironment for tumor pro-
gression, where TAMs are always found [16, 17]. Accmu-
lating evidences indicate that the TAMs can induce the
cancer cells to undergo EMT and subsequently enhance
the invasion and metastasis of breast cancer, cholangio car-
cinoma and hepatocellular carcinoma [16–19]. However,
the interaction between the TAMs and cancer cells under-
going EMT in the OSCC progression remains unknown.
In the present study, we aim to investigate the inci-
dence of CD68 and CD163 in relation to clinicopatho-
logical features and outcomes, then further insight into
the interaction between TAMs and cancer cells undergo-
ing EMT in OSCC progression. Explore the underlying
mechanisms may identify innovative strategies to im-
prove therapeutic efficacy of OSCC.
Methods
Patients and tissue specimens
One hundred twenty-seven primary OSCC specimens and
23 peritumoral tissue specimens were obtained from the
Department of Oral Pathology and the Department of Oral
Maxillofacial Surgery, Affiliated Hospital of Stomatology,
Nanjing Medical University. The patients with primary
OSCC had been treated with a wide excision surgery, with
simultaneous an elective dissection of the regional lymph
nodes or a classical radical neck dissection from August
2007 to April 2013 (74 men and 53 women; mean age,
61 years; rang, 34–88 years). None of the patients had re-
ceived any preoperative radiation-chemotherapy. Peritu-
moral tissue samples were obtained from unaffected tissue
surrounding the tumors. All the primary tumors were lo-
cated in the tongue (n = 52), gingiva (n = 26), buccal mu-
cosa (n = 31), lip (n = 4), floor of the mouth (n = 2), and
others (n = 12). The tumor nest is the place at which tumor
cells originates, accumulates, or develops, as the center on
which a tumor forms. The tumor stroma is the micro-
environment around the tumor cells. The TNM classifica-
tion and clinical staging were carried according to the
International Union Against Cancer (UICC). The patho-
logical grade was classified into groups according to the
WHO classification. The follow-up period ranged from 2
to 91 months (average: 41.2 months; median: 39 months).
A total of 99 patients had at least a 2-year follow-up after
treatment. This study protocol was approved according to
the Ethics Committee of the Nanjing Medical University.
Immunohistochemistry
The specimens were fixed in a 10 % formaldehyde solution
and embedded in paraffin. Then, Paraffin tissue sections
(4–5 μm) with xylene dewaxing and with graded alcohols
rehydrating. Endogenous peroxidases were blocked for
10 min using 3 % hydrogen peroxide. Antigen retrieval with
0.01 M sodium citrate retrieval buffer (pH 6.0) was carried
out by microwave heating for 20 min. The sections were
then incubated overnight with antibodies for E-cadherin
(Cell Signaling Technology, Danvers, MA, USA), vimentin
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), CD68
(Abcam, Cambridge, MA, USA), CD163 (Abcam) at 4 °C,
and then incubated with appropriate secondary antibodies.
Subsequently, the reaction product was visualized by incu-
bation with 3,3’-diaminobenzidine and then counter-
stained with haematoxylin. Positive and negative controls
were used in each staining run.
Evaluation of immunoreactivity
The immunoreactivity of the E-cadherin, vimentin, CD68
and CD163 in cancer cells was evaluated using the same
method which was described in our previous studies [13].
Immunoreactivity was semiquanitatively evaluated by
using immunoreactive score. The final immunoreactivity
was divided into negative (score = 0), low (1 ≤ score ≤ 4)
and high (score > 4). CD68-positive and CD163-positive
macrophages were quantified by two pathologists who
were blinded to the clinical patient data. They detected
each section at low magnification (100×) and identified
the areas with the highest macrophage density. The
number of macrophages was counted in ten random high-
power fields (HPFs, 400×), the mean number of macro-
phages per HPF was evaluated after two counts. On the
basis of the number of macrophages, the samples were di-
vided into low and high groups by using cut-off values of
6/HPF in tumor nest and 8/HPF in tumor stroma.
Cell cultures and preparation of TAMs
Human monocyte/macrophage cell line THP-1 was ob-
tained from the Institute of Biochemistry and Cell Biol-
ogy, Chinese Academy of Sciences, Shanghai, China.
Human SCC9 was obtained from the American Type
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Culture Collection (ATCC, Manassas, VA, USA). Human
HN4 and HN6 were kindly provided from the Shanghai
Ninth People's Hospital, Shanghai, China. The HN4,
HN6 and SCC9 cancer cells were maintained in a 1:1
mixture of Dulbecco’s modified Eagle’s medium and
Ham’s F12 medium (Invitrogen, Burlington, Ontario,
Canada) supplemented with 10 % fetal bovine serum
(FBS, Invitrogen), 400 ng/mL hydrocortisone (Sigma-
Aldrich, St Louis, MO, USA) and 1 % penicillin/strepto-
mycin solution (Invitrogen). The THP-1 cells were
maintained in RPMI‑1640 medium (Invitrogen) sup-
plemented with above FBS and antibodies. To obtain
TAMs cells, we treated the THP-1 cells with phorbol-
myristate acetate (PMA, 10 ng/mL, Sigma, USA) for
48 h, and then added the macrophage colony-stimulating
factor (M-CSF, 10 ng/mL Sigma, USA) into the medium
for 24 h. After a thorough wash with PBS for two times,
the adherent cells were cultured in RPMI‑1640 medium
supplemented with FBS and antibodies. Five days later, the
cells were collected and detected the expression of CD68
and CD163 (experimental procedure was detailed in im-
munofluorescence microscopy), and the conditioned
medium (CM) from macrophages was harvested, clarified
by centrifugation, used for mass spectral protein analysis
(Invitrogen) and treating with the cancer cells. The HN4,
HN6 and SCC9 cancer cells treating with CM were
regarded as the experimental group (HN4-M, HN6-M
and SCC9-M cells) for subsequent studies.
Quantitative real-time PCR
The total RNA was extracted from cells by using the
TRIzol reagent (Invitrogen), and mRNA was reverse
transcribed into cDNA synthesis by using the 5 × Prime-
Script RT Master Mix (TaKaRa, Otsu, Shiga, Japan) at
37 °C for 15 min and 85 °C for 5 s, according to the cor-
responding manufacturer’s protocol. Quantitative PCR
(qPCR) was performed to evaluate the gene expression
using 2 × SYBR Premix Ex Taq (TaKaRa) with a 7300 ABI
Real-Time PCR System (Applied Biosystems, Foster City,
CA, USA) following the conditions: 95 °C for 30 s, 95 °C
for 5 s, and 60 °C for 31 s for 40 cycles. The relative
mRNA levels were checked by the 2 (−ΔΔCT) method







Western blotting was performed as described in our previ-
ous study [14]. The blots were first probed with primary
Fig. 1 CD68-positive macrophages and CD163-positive macrophages were examined by immunohistochemistry. CD68 staining a1, a2, a3 and nega-
tive staining of CD163 was found in peritumoral stroma (b1, b2, b3). CD68-positive macrophages (c1, c2, c3) and CD163-positive macrophages (d1, d2,
d3) were found both in tumor nest and stroma. (a1-d1, 100×; a2-d2, 200×; a3-d3, 400× )
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Table 1 Correlation between clinical parameters and CD68+ macrophages counts in tumor nest and tumor stroma
Variable No. CD68+ macrophages counts in tumor nest CD68+ macrophages counts in tumor stroma
Low(≤6/HPF) High(>6/HPF) P Low(≤8/HPF) High(>8/HPF) P
Sex 0.176 0.060
Male 74 34 40 30 44
Female 53 18 35 13 40
Age (years) 0.773 0.927
≤50 26 10 16 9 17
>50 101 42 59 34 67
Tumor location 0.034 0.346
Tongue 52 29 23 20 32
Gingiva 26 7 19 8 18
Buccal mucosa 31 8 23 6 25
Lip 4 3 1 2 2
Floor of the mouth 2 1 1 1 1
Others 12 4 8 6 6
Tumor size 0.665 0.369
T1 21 9 12 7 14
T2 68 28 40 21 47
T3 26 12 14 8 18
T4 12 3 9 7 5
Lymph node metastasis 0.850 0.321
N0 72 30 42 27 45
N (+) 55 22 33 16 39
Metastasis 0.793 0.627
M0 125 51 74 42 83
M (+) 2 1 1 1 1
Clinical stage 0.262 0.699
I 12 5 7 4 8
II 42 19 23 17 25
III 34 16 18 8 26
IV 39 12 27 14 25
Pathological grade 0.135 0.296
I 76 34 42 24 52
II 42 18 24 13 29
III 9 0 9 6 3
Recurrence 0.111 0.259
No 83 39 44 25 58
Yes 42 13 29 18 24
Lost 2 0 2 0 2
Follow-up 0.005 0.218
Live 91 45 46 27 64
Dead 33 7 26 15 18
Lost 3 0 3 1 2
No., number of patients; HPF, high-power field. N0, no lymph node metastasis; N (+), node metastasis. M0, no metastasis; M(+), metastasis
Bold values signify P < 0.05
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Table 2 Correlation between clinical parameters and CD163+ macrophages counts in tumor nest and tumor stroma
Variable No. CD163+ macrophages counts in tumor nest CD163+ macrophages counts in tumor stroma
Low(≤6/HPF) High(>6/HPF) P Low(≤8/HPF) High(>8/HPF) P
Sex 0.037 0.846
Male 74 36 38 32 42
Female 53 16 37 22 31
Age (years) 0.874 0.674
≤50 26 11 15 12 14
>50 101 41 60 42 59
Tumor location 0.389 0.057
Tongue 52 24 28 22 30
Gingiva 26 9 17 17 9
Buccal mucosa 31 9 22 7 24
Lip 4 3 1 2 2
Floor of the mouth 2 1 1 1 1
Others 12 6 6 5 7
Tumor size 0.921 0.335
T1 21 7 14 7 14
T2 68 31 37 30 38
T3 26 8 18 9 17
T4 12 6 6 8 4
Lymph node metastasis 0.200 0.889
N0 72 33 39 31 41
N (+) 55 19 36 23 32
Metastasis 0.235 0.829
M0 125 52 73 53 72
M (+) 2 0 2 1 1
Clinical stage 0.059 0.725
I 12 5 7 4 8
II 42 21 21 21 21
III 34 16 18 13 21
IV 39 10 29 16 23
Pathological grade 0.211 0.469
I 76 35 41 35 41
II 42 13 29 14 28
III 9 4 5 5 4
Recurrence 0.22 0.01
No 83 38 45 28 55
Yes 42 13 29 24 18
Lost 2 1 1 2 0
Follow-up 0.04 0.040
Live 91 43 48 34 57
Dead 33 8 25 17 16
Lost 3 1 2 3 0
No., number of patients; HPF, high-power field. N0, no lymph node metastasis; N (+), node metastasis. M0, no metastasis; M(+), metastasis
Bold values signify P < 0.05
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antibodies, such as anti-β-actin as control (1:1000, Santa
Cruz Biotechnology), anti-E-cadherin (1:1000, Cell Signal-
ing Technology), anti-vimentin (1:500, Santa Cruz Bio-
technology), and then probed with appropriate secondary
antibodies. The membranes were then developed by
Immun-Star WesternC Kit (Bio-Rad, Hercules, CA, USA)
products and bands were analyzed by exposure to film
(Kodak, Japan).
Immunofluorescence microscopy
Cells were grown on glass coverslips, fixed with 4 % para-
formaldehyde (PFA) for 20 min at room temperature, per-
meabilised in 1 % Triton X-100 for 15 min, blocked with
goat serum albumin for 30 min at 37 °C, then incubated
with antibodies specific for CD68 (1:100, Abcam), CD163
(1:50, Abcam), E-cadherin (1:100, Cell Signaling Technol-
ogy) and vimentin (1:100, Santa Cruz Biotechnology)
Table 3 Relationship between CD68+, CD163+ macrophages counts in tumor nest and peritumoral epithelia
Variable No. CD68+ macrophages counts CD163+ macrophages counts
High(>6/HPF) Low(≤6/HPF) P High(>6/HPF) Low(≤6/HPF) P
0.000 0.000
Normal 23 0 23 0 23
Tumor 127 75 52 75 52
Relationship between CD68+, CD163+ macrophages counts in tumor stroma and peritumoral stroma
Variable No. CD68+ macrophages counts CD163+ macrophages counts
High(>8/HPF) Low(≤8/HPF) P High(>8/HPF) Low(≤8/HPF) P
0.374 0.000
Normal 23 12 11 0 23
Tumor 127 84 43 73 54
No., number of patients; HPF, high-power field
Bold values signify P < 0.05
Fig. 2 CD68 and CD163 expression was examined in tumor cells by immunohistochemistry. High expression of CD68 a1, a2, a3 and low expression of
CD163 (b1, b2, b3) was found in tumor cells. Low expression of CD68 (c1, c2, c3) and high expression of CD163 (d1, d2, d3) was found in tumor cells.
(a1-d1, 100×; a2-d2, 200×; a3-d3, 400×)
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Table 4 Relationship between CD68, CD163 expression levels of tumors and clinical variables
Variable No. CD68 CD163
N L H P N L H P
Sex 0.081 0.008
Male 74 15 19 40 35 25 14
Female 53 6 8 39 13 18 22
Age (years) 0.668 0.642
≤50 26 5 4 17 8 9 9
>50 101 16 23 62 40 34 27
Tumor location 0.324 0.405
Tongue 52 10 12 30 20 17 15
Gingiva 26 3 2 21 8 11 7
Buccal mucosa 31 3 8 20 11 9 11
Lip 4 2 1 1 4 0 0
Floor of the mouth 2 0 1 1 0 1 1
Others 12 3 3 6 5 5 2
Tumor size 0.419 0.124
T1 21 5 3 13 9 4 8
T2 68 9 14 45 23 24 21
T3 26 4 5 17 14 7 5
T4 12 3 5 4 2 8 2
Lymph node metastasis 0.044 0.098
N0 72 15 19 38 33 22 17
N (+) 55 6 8 41 15 21 19
Metastasis 0.542 0.535
M0 125 21 27 77 48 42 35
M (+) 2 0 0 2 0 1 1
Clinical stage 0.564 0.114
I 12 4 2 6 7 2 3
II 42 7 10 25 17 14 11
III 34 4 7 23 14 9 11
IV 39 6 8 25 10 18 11
Pathological grade 0.986 0.537
I 76 12 17 47 31 25 20
II 42 8 6 28 15 16 11
III 9 1 4 4 2 2 5
Recurrence 0.870 0.01
No 83 14 16 53 35 32 16
Yes 42 7 11 24 13 10 19
Lost 2 0 0 2 0 1 1
Follow-up 0.560 0
Live 91 16 17 58 41 33 17
Dead 33 5 10 18 7 9 17
Lost 3 0 0 3 0 1 2
No., number of patients; N, negative; L low expression; H, high expression. N0, no lymph node metastasis; N (+), node metastasis. M0, no metastasis; M(+), metastasis
Bold values signify P < 0.05
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followed by the appropriate secondary antibodies (1:50)
and then further stained with DAPI (1:1000, Invitrogen)
for 2 min. Cells were visualized using a Zeiss LSM-710
confocal microscope.
Wound-healing and invasion assays
The cells were grown in 6-well plates to 90 % confluence
and scraped with a pipette tip across the cell surface.
After wounding, the suspension cells and debris were
carefully removed, and the cells were incubated with
serum-free medium. Migrating cells at the wound front
were photographed after 24 h. Cells invasion assay was
carried using Transwell filters (6.5-mm diameters, 8-μM
pore sizes, Costar, Lowell, MA, USA). The filters were
pre-coated for 30 min at 37 °C with Matrigel Basement
Membrane Matrix (20 μL per square centimeter, BD
Biosciences, MA, USA) mixed with serum free medium
(1:3). Cells (4 × 105) were washed with PBS, resuspended
with 100 μL serum-free medium and added to the upper
chamber, while a medium containing 10 % FBS was
placed as a chemoattractant in the lower chamber. After
incubating for 24 h at 37 °C in 5 % CO2, the chambers
were fixed in 4 % PFA and stained with crystal violet
(Sigma-Aldrich) for 30 min. The remaining cells and
matrigel on the upper chamber were removed using
cotton swabs, and the migratory cells present on the lower
surface of the membrane were counted in ten random
fields and photographed at 100x magnification (Olympus).
Statistical analysis
The relationship between the CD68-positive macrophages,
CD163-positive macrophages, CD68, CD163, E-cadherin,
vimentin expression and clinicopathological parameters
was analysed using the ANOVA, chi-square test, Fisher’s
exact test, Cochran-Mantel-Haenszel chi-squared test. The
associations between CD163, E-cadherin and vimentin ex-
pression were analysed using the Spearman rank correl-
ation analysis. The overall survival rate was estimated using
the Kaplan–Meier method and compared by the log-rank
test. The prognostic analysis was carried out with univariate
Cox regression models. All the data were analyzed using
SPSS statistical software (for Windows, version 16.0). P-
value less than 0.05 was considered statistically significant.
Results
CD68-positive macrophages and CD163-positive
macrophages in oral squamous cell carcinoma and
peritumoral tissue
In this study, we assessed the expression of two TAMs
markers CD68 and CD163 in tumor or peritumoral tissue
Fig. 3 CD68-positive macrophages, CD163-positive macrophages, E-cadherin and vimentin was examined by immunohistochemistry. In oral
squamous cell carcinoma patients, the absence or reduced expression of CD68-positive macrophages a1, a2, a3 and increased expression of
CD163-positive macrophages (b1, b2, b3) was observed in tumor tissue, where have no expression of E-cadherin (c1, c2, c3), but strong
cytoplasmic staining of vimentin (d1, d2, d3). (a1-d1, 100×; a2-d2, 200×; a3-d3, 400×)
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specimens. Of note, CD68-positive macrophages were de-
tected only in peritumoral stroma (Fig. 1 a1, a2, a3), where
had no CD163-positive macrophages (Fig. 1 b1, b2, b3).
However, CD68 and CD163 were detected on the plasma
membrane or in the cytoplasm of the macrophages both
in tumor nest and stroma (Fig. 1 c1, c2, c3; 1d1, d2, d3).
The number of CD68-positive macrophages in the nest
and stroma of tumor was increased in 59 % (75 out of
127) and 66 % (84 out of 127) of samples, respectively.
Interestingly, the increase of CD68-positive macrophages
in the nest but not stroma correlates with the tumor lo-
cation (P = 0.034) and mortality (P = 0.005, Table 1). In
contrast, the density of CD163-positive macrophages in
the tumor nest and stroma was higher in 59 % (75 out
of 127) and 57 % (73 out of 127) of total samples (Table 2).
Importantly, the density of CD163-positive macrophages
in tumor nest was significantly associated with the
sex (P = 0.037) and mortality (P = 0.044), while that in
the tumor stroma was significantly correlated with the re-
currence (P = 0.008) and mortality (P = 0.04). In addition,
we analyzed the expression of CD68 and CD163 in 23
peritumoral tissue samples (Table 3). 52 % (12 out of
23, P = 0.374) of samples showed relatively high density
of CD68-positive macrophages in peritumoral stroma,
however, the density of CD163-positive macrophages
(P < 0.001) was none in all samples. Based on these re-
sults, we conclude that the infiltration CD163-positive
macrophages have a prognostic significance.
Expression of CD68 and CD163 in oral squamous cell
carcinoma patients
In addition to TAMs, tumor cells also expressed CD68
(Fig. 2 a1, a2, a3; 2c1, c2, c3) and CD163 (Fig. 2 b1, b2,
b3;2 d1, d2, d3) on the plasma membrane and in the
cytoplasm as detected by the immunohistochemical
staining. CD68-positive tumor cells were detected in
83 % of samples, of which 79 cases (Fig. 2 a1, a2, a3) and
27 cases (Fig. 2 c1, c2, c3) showed relatively high and
low expression of CD68. In contrast, CD163-positive
tumor cells were found in 62 % of samples, of which 36
cases (Fig. 2 d1, d2, d3) and 43 cases (Fig. 2 b1, b2, b3)
have increased and decreased expression of CD163. The
expression levels of CD68 in tumor cells were only associ-
ated with lymph node metastasis (P = 0.044, Table 4),
while the expression of CD163 was significantly associated
with the recurrence (P = 0.013) and mortality (P = 0.001).
This is the first time showed that a fraction of OSCC
tumor cells exhibited definite CD68 and CD163 expres-
sion. More important, the high expression of CD163 was
correlated with poor survival.
Fig. 4 Expression of CD68, CD163, E-cadherin and vimentin in tumor cells. Increased expression of CD68 a1, a2, a3 and CD163 (b1, b2, b3)
was observed in tumor cells, whereas there was absence or reduced expression of E-cadherin (c1, c2, c3), but strong cytoplasmic expression
of vimentin (d1, d2, d3) at the invasive front of oral squamous cell carcinoma (a1-d1, 100×; a2-d2, 200×; a3-d3, 400×)
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Table 5 Relationship between E-cadherin, vimentin expression levels of tumors and clinical variables
Variable No. E-cadherin Vimentin
N L H P N L H P
Sex 0.990 0.205
Male 74 16 21 37 37 22 15
Female 53 12 15 26 19 17 17
Age (years) 0.257 0.383
≤50 26 7 4 15 12 10 4
>50 101 21 32 48 44 29 28
Tumor location 0.444 0.345
Tongue 52 13 12 27 26 16 10
Gingiva 26 3 6 17 12 10 4
Buccal mucosa 31 9 11 11 10 8 13
Lip 4 1 1 2 1 2 1
Floor of the mouth 2 1 1 0 2 0 0
Others 12 1 5 6 5 3 4
Tumor size 0.848 0.819
T1 21 3 7 11 10 6 5
T2 68 18 19 31 27 24 17
T3 26 5 7 14 12 5 9
T4 12 2 3 7 7 4 1
Lymph node metastasis 0.150 0.010
N0 72 20 17 35 40 19 13
N (+) 55 8 19 28 16 20 19
Metastasis 0.678 0.050
M0 125 28 35 62 56 39 30
M (+) 2 0 1 1 0 0 2
Clinical stage 0.071 0.046
I 12 3 1 8 9 2 1
II 42 15 10 17 21 12 9
III 34 4 12 18 13 10 11
IV 39 6 13 20 13 15 11
Pathological grade 0.441 0.001
I 76 16 19 41 40 25 11
II 42 11 13 18 15 13 14
III 9 1 4 4 1 1 7
Recurrence 0.922 0.05
No 83 18 24 41 43 24 16
Yes 42 9 12 21 13 14 15
Lost 2 1 0 1 0 1 1
Follow-up 0.747 0.014
Live 91 18 27 46 47 27 17
Dead 33 9 9 15 9 11 13
Lost 3 1 0 2 0 1 2
No., number of patients; N, negative; L low expression; H, high expression; N0, no nodal metastasis; N(+), nodal metastasis. M0, no metastasis; M(+), metastasis
Bold values signify P < 0.05
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Table 6 Relationship between E-cadherin, vimentin expression levels of the tumors invasive front and clinical variables
Variable No. E-cadherin Vimentin
N L H P N L H P
Sex 0.554 0.024
Male 74 20 28 26 37 18 19
Female 53 15 24 14 19 8 26
Age (years) 0.988 0.209
≤50 26 7 11 8 12 8 6
>50 101 28 41 32 44 18 39
Tumor location 0.123 0.508
Tongue 52 15 21 16 26 9 17
Gingiva 26 6 6 14 12 7 7
Buccal mucosa 31 11 15 5 10 6 15
Lip 4 1 1 2 1 2 1
Floor of the mouth 2 1 1 0 2 0 0
Others 12 1 8 3 5 2 5
Tumor size 0.970 0.818
T1 21 5 8 8 10 4 7
T2 68 21 28 19 27 16 25
T3 26 6 13 7 12 4 10
T4 12 3 3 6 7 2 3
Lymph node metastasis 0.236 0.003
N0 72 23 25 24 40 15 17
N (+) 55 12 27 16 16 11 28
Metastasis 0.665 0.159
M0 125 35 51 39 56 26 43
M (+) 2 0 1 1 0 0 2
Clinical stage 0.236 0.043
I 12 3 3 6 9 2 1
II 42 17 13 12 21 8 13
III 34 5 19 10 13 6 15
IV 39 10 17 12 13 10 16
Pathological grade 0.659 0.007
I 76 20 29 27 40 16 20
II 42 13 20 9 15 10 17
III 9 2 3 4 1 0 8
Recurrence 0.460 0.01
No 83 22 32 29 43 19 21
Yes 42 12 20 10 13 6 23
Lost 2 1 0 1 0 1 1
Follow-up 0.301 0.001
Live 91 22 39 30 47 21 23
Dead 33 12 13 8 9 4 20
Lost 3 1 0 2 0 1 2
No., number of patients; N, negative; L low expression; H, high expression. N0, no nodal metastasis; N(+), nodal metastasis. M0, no metastasis; M(+), metastasis
Bold values signify P < 0.05
Hu et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:12 Page 11 of 19
Expression of E-cadherin and vimentin in oral squamous
cell carcinoma patients
It has been reported that the number of TAMs is associ-
ated with EMT in tumor samples [16]. So we are won-
dering whether this relationship also exists in OSCC.
Therefore, E-cadherin and vimentin, markers of EMT
were detected by IHC. As shown in Fig. 3, the absence
or reduced expression of CD68-positive macrophages
(Fig. 3 a1, a2, a3) and increased expression of CD163-
positive macrophages (Fig. 3 b1, b2, b3) was observed in
tumor tissue, where have no expression of E-cadherin
(Fig. 3 c1, c2, c3), but strong cytoplasmic staining of
vimentin (Fig. 3 d1, d2, d3). Otherwise, Increased ex-
pression of CD68 (Fig. 4 a1, a2, a3) and CD163 (Fig. 4
b1, b2, b3) was also observed in tumor cells, whereas
there was absence or reduced expression of E-cadherin
(Fig. 4 c1, c2, c3), but strong cytoplasmic expression of
vimentin (Fig. 4 d1, d2, d3) at the invasive front of the
tumor. In the cancerous tissue, 99 out of 127 tumors
express E-cadherin (78 %), the low expression, 36
cases; the high expression, 63 cases; and the negative
expression, 28 (22 %) cases. Then, we check the ex-
pression levels of the tumors invasive front, 92 out of
127 (72 %) exhibit E-cadherin expression, the low ex-
pression, 52 cases; the high expression, 40 cases; and
the negative expression, 35 (28 %) cases. As shown in
Table 5 and Table 6, there was no significant relation-
ship between the expression of E-cadherin and clinical
variables, including sex, age, tumor location, tumor size,
lymph node, metastasis, clinical stage, pathological
grade, recurrence and mortality. Meanwhile, of the 127
tumors, 71 (56 %) cases express vimentin, the low ex-
pression, 39 cases; the high expression, 32 cases; and
the negative expression, 56 (44 %) cases. Besides, high
cytoplasmic staining of vimentin was also observed at
the invasive front of tumors in 35 % (45 out of 127) pa-
tients. Despite no significant correlation with sex, age,
and location and size of tumor, the expression of vimen-
tin was associated with the metastasis into lymph nodes,
clinical stage, pathological grade, recurrence and mor-
tality. Especially at the tumor invasion front, the in-
creased expression of vimentin was observed in 55 %
(23 out of 42) patients with recurrence, and in 61 % (20
out of 33) patients with poor survival.
Association between the expression of CD163, E-cadherin
and vimentin
To investigate the role of TAMs in tumor progres-
sion, the relationship between the CD163, E-
cadherin and vimentin was analyzed. As shown in
Table 7, the levels of CD163 expression in tumor
cells were positively associated with the expression
of E-cadherin (P = 0.04 and P = 0.038, respectively)
and vimentin (P < 0.001 and P < 0.001, respectively)
in tumors and at the tumor invasion front. However,
the CD163-positive macrophages have no association
with E-cadherin and vimentin (data not shown).
Survival analysis
To predict the prognostic value, survival analysis was
carried by univariate Cox’s proportional hazard regres-
sion models in all the 127 patients with OSCC. The
overall survival curve for the 127 samples was shown in
Fig. 5a. The expression levels of CD68-positive macro-
phages (P = 0.009, Fig. 5b) and CD163-positive macro-
phages (P = 0.015, Fig. 5d) in tumor nest was
significantly associated with poor prognosis. Further-
more, the expression levels of CD163 (Fig. 5g) in tumor
cells (P = 0.001), vimentin both in tumor (P = 0.006,
Fig. 5j) and at the tumor invasion front (P = 0.002,
Fig. 5k) had a worse prognostic impact on the survival
rate. However, the number of CD68-positive macro-
phages (Fig. 5c) and CD163-positive macrophages
(Fig. 5e) in tumor stroma, and the levels of CD68
(Fig. 5f ) and E-cadherin (Fig. 5h, 5i) expression in tumor
cells did not shown any significant correlation with over-
all survival (Table 8).
The establishment and characterization of TAMs
Human THP-1 cells are always used as models to inves-
tigate the monocyte/macrophages differentiation [20]. In
the current study, THP-1 cells quickly extended pseudo-
podia and became attached after the treatment with
phorbolmyristate acetate (PMA, 10 ng/mL) for 48 h.
Thereafter, the macrophage colony-stimulating factor
(M-CSF) stimulates them to further differentiate into ad-
herent macrophages (Fig. 6a). The expression of CD68
and CD163 on these macrophages was detected by im-
munofluorescence. As shown in Fig. 6b, these macro-
phages expressed not only CD68 (red) but also CD163
(green). Using mass spectral analysis, a variety of inflam-
matory cytokines and chemokines, including TGF-β,
TNF, IL and so on (Fig. 6c) were present in the collected
CM. Taken together, we confirmed that the TAMs were
established and exhibited anti-inflammatory (M2)
phenotype [20].





At tumor invasive front 0.038
Vimentin
In tumor 0.000
At tumor invasive front 0.000
Bold values signify P < 0.05
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TAMs induce the cancer cells undergo EMT in oral
squamous cell carcinoma
To clarity whether TAMs could induce the cells under-
went EMT in OSCC, we treated the HN4, HN6 and
SCC9 cells with the CM from TAMs and the morph-
ology was observed. HN4-M, HN6-M and SCC9-M cells
lose tight cellular junctions and became scattered and

































































































































































































































































Fig. 5 Survival cures of 127 oral squamous cell carcinoma patients. a Overall survival (OS) curves of 127 oral squamous cell carcinoma patients. In
OSCC patients, the expression of CD68-positive macrophages and CD163-positive macrophages in tumor nest, CD163 in tumor cells, vimentin
both in tumor and at the tumor invasion front was associated with poor OS (b, d, g, j, k). The expression of CD68-positive macrophages and
CD163-positive macrophages in tumor stroma, CD68 in tumor cells, E-cadherin both in tumor and at the tumor invasion front was not associated
with poor OS (c, e, f, h, i). L, low (≤ 6/ high-power field); H, high (≥ 8/ high-power field); N, negative; L, low expression; H, high expression. CD68
+ 1: CD68-positive macrophages counts in tumor nest; CD68+ 2: CD68-positive macrophages counts in tumor stroma; CD163+ 1: CD163-positive
macrophages counts in tumor nest; CD163+ 2: CD163-positive macrophages counts in tumor stroma; CD68: CD68 expression in tumors; CD163:
CD163 expression in tumors; E-cad 1: E-cadherin expression in tumor; E-cad 2: E-cadherin expression at the invasive front of tumor; vim 1:
vimentin expression in tumor; vim 2: vimentin expression at the invasive front of tumor
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Table 8 Univariate cox regression analysis of overall survival
covariate P-value Risk ratio 95 % CI
Sex (male, female) 0.4 1.35 (0.655, 2.043)
Age (≤50 or younger,>50) 0.13 2.49 (1.300, 3.680)
Tumor location Post1 0.75 1.16 (0.244, 2.082)
Tumor location Post2 0. 448 1.38 (0.551, 2.201)
Tumor location Post3 0.98 0 (−1242.048, 1242.048)
Tumor location Post4 0.99 0 (−1596.148, 1596.148)
Tumor location Post5 0.77 0.8 (−0.692, 2.288)
Tumor size (T1-T4) 0.45 1.18 (0.757, 1.595)
Nodal metastasis (N0, N(+)) 0.44 1.31 (0.618, 2.006)
Metastasis (M0, M(+)) 0.69 0.05 (0.760, 1.470)
Clinical stage (I, II, III, IV) 0.55 1.12 (1.146, 2.200)
Pathological grade 0.06 1.67 (0.244, 2.082)
CD68+ macrophages counts in tumor nest (Low, High) 0.01 3.08 (2.236, 3.914)
CD68+ macrophages counts in tumor stroma (Low, High) 0.3 0.69 (−0.010, 1.390)
CD163+ macrophages counts in tumor nest (Low, High) 0.02 2.83 (1.991, 3.669)
CD163+ macrophages counts in tumor stroma (Low, High) 0.48 0.78 (0.085, 1.473)
CD68 expression in tumor (Negative, Low, High) 0.97 1.01 (0.555, 1.465)
CD163 expression in tumor (Negative, Low, High) 0 2.2 (1.735, 2.667)
E-cadherin expression in tumor (Negative, Low, High) 0.61 0.89 (0.465, 1.323)
E-cadherin expression at the invasive front of tumor (Negative, Low, High) 0.19 0.74 (0.280, 1.1937)
Vimentin expression in tumor (Negative, Low, High) 0.01 1.79 (1.373, 2.207)
Vimentin expression at the invasive front of tumor (Negative, Low, High) 0 1.88 (1.474, 2.295)
Bold values signify P < 0.05
Fig. 6 The establishment and characterization of tumor-associated macrophages. a The PMA-treated THP-1 cells were differentiated into adherent
macrophages. b The Double immunofluorescence staining of CD68 (red) and CD163 (green) in the TAMs. The nuclei were stained with DAPI. The photographs
were taken at 200x magnification. c The inflammatory cytokines and chemokines were detected in conditioned medium by using mass spectral analysis
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further determine the EMT, the pattern of gene expres-
sion was analyzed by real-time PCR. The expression of
E-cadherin decreased slightly, while vimentin expression
increased sharply in HN4-M (3.46-fold, P < 0.05), HN6-M
(1.99-fold, P < 0.05), and SCC9-M (2.22-fold, P < 0.05)
cells (Fig. 7b). In line with the gene expression, Western
blot analysis showed that the HN4-M, HN6-M and SCC9-
M cells exhibited a significant decrease of E-cadherin, but
an increase of the mesenchymal marker vimentin (Fig. 7c).
In addition, we used double-staining immunofluorescence
analysis to investigate the pattern of E-cadherin and
vimentin. As Fig. 8 shown, the HN4-M, HN6-M and
SCC9-M cells showed typical fibroblast-like and spindle-
shaped appearance, with reduced E-cadherin but en-
hanced vimentin. Taken together, these results indicated
that the TAMs could induce EMT in OSCC.
TAMs enhance the cancer cells migration and invasion in
vitro
To verify the migration of cancer cells, a wound-healing
assay was used. The CM promotes the cancer cells to mi-
grate and the wound was closed easily after 24 h as com-
pared to untreated cancer cells (Fig. 9a). Furthermore,
Transwell assays were carried to measure the invasive abil-
ity of the cells. After 24 h, the invasive cells were quantified
and captured with × 100 magnification in five randomly
chosen fields (Fig. 9b). After the treatment of CM, the
cancer cells showed an increase in invasion with HN4-
M (4.34-fold, P < 0.001), HN6-M (2.76-fold, P < 0.001)
and SCC9-M (6.55-fold, P < 0.001) cells (Fig. 9c). These
results demonstrated that the TAMs could induce EMT
and enhance the migration and invasion of OSCC.
Discussion
Increasing studies have shown that TAMs play a signifi-
cant role in tumor progression and correlate with poor
prognosis in numerous cancers. However, the interaction
between the TAMs and clinicopathological features and
the induction of EMT in OSCC has not been elucidated
clearly. Exploration of the underlying mechanisms may
reveal new targets for the therapy of oral cancers.
In the OSCC specimens, we found that the high num-
ber of CD68-positive macrophages in tumor nest was
positively associated with tumor location and mortality.
Using univariate cox analysis also revealed that the high
number of CD68-positive macrophages was correlated
with a poor overall survival. Meanwhile, the tumor
stroma was also infiltrated by CD68-positive macro-
phages. However, a significant correlation between the
high number of CD68-positive macrophages and the
clinicopathological parameters and overall survival was
not shown in stroma. These results were in accordance
with the previous studies in solid malignancies that
CD68 was frequently used as a marker to identify TAMs,
Fig. 7 TAMs induce the cancer cells undergo epithelial to mesenchymal transition (EMT). a The HN4, HN6 and SCC9 cells presented typical cobblestone
and epithelial-like appearances. The HN4-M, HN6-M and SCC9-M cells were scattered and spindle shaped, exhibited fibroblast-like appearances. The
photographs were taken at 40x magnification. b The relative mRNA expression levels of E-cadherin, and vimentin was performed by real-time RT-PCR.
The housekeeping gene GAPDH was used as the control. The data were reported as mean ± SD. c The EMT-related proteins E-cadherin and vimentin
were examined by the Western blot, β-actin was used as a loading control. The data were reported as mean ± SD. * P < 0.05, ** P < 0.01
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and the dense infiltration of CD68-positive macrophages
in the tumor was associated with poor survival [21, 22].
Previous studies have confirmed the TAMs include the
M2 phenotype and CD163 is regarded as a specific
marker of M2 macrophages. The present study showed
the density of CD163-positive macrophages both in
tumor nest and stroma significantly correlated with the
overall survival. Our results support the previous re-
searches that the infiltration of CD163-positive macro-
phages associated with poor prognosis in various
tumors, such as hepatocellular carcinoma, renal cell car-
cinoma and bladder cancer [11, 23, 24]. Of note, the
CD163-positive macrophages may be more suitable to
identify the TAMs than the CD68-positive macrophages
in OSCC and the infiltration of CD163-positive macro-
phages in tumor may be more important for tumor pro-
gression [8, 10, 11].
It has been reported that both CD68 and CD163 ex-
press on circulating monocytes and macrophages and
used as TAMs markers in tumor progression [25, 26].
The present study demonstrated that CD68 and CD163
not only express in TAMs, but also in cancer cells. Inter-
estingly, the expression of CD68 in tumor cells was only
significantly associated with lymph node metastasis, but
not with recurrence and survival. Although few previous
studies have shown that the CD68 expressed in tumor
cells, our novel findings was supported by Strojnik and
coworkers, whose researches confirmed that the cancer
cells exhibit expression of CD68 and the high CD68
staining of cancer cells correlated with poor prognosis
[27]. Furthermore, CD163 was also present in tumor
samples. Importantly, the expression of CD163 in cancer
cells was significantly associated with recurrence and
mortality. The univariate cox analysis also shows that
the high expression of CD163 in cancer cells has a sig-
nificant prognostic impact on overall survival. Based on
our knowledge, this is the first study that demonstrated
the expression of CD163 in cancer cells and its correl-
ation with poor prognosis in OSCC, which is consistent
with the studies in breast cancer, colorectal cancer and
malignant melanoma [6, 9, 28, 29]. Macrophage antigens
CD163 expressed in tumor cells may be a heterotypic
cell fusion between the TAMs and tumor cells and this
fusion may enhance the metastatic potential of tumor
cells [12]. Another explanation is the cancer cells may
be reprogrammed by the TAMs and transdifferentiate to
Fig. 8 The Double immunofluorescence staining of E-cadherin (red) and vimentin (green) in the cells. The nuclei were stained with DAPI. The
HN4-M, HN6-M and SCC9-M cells were scattered, exhibited fibroblast-like appearances, showed increased expression of vimentin and decreased
expression of E-cadherin (400x magnification)
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a more mesenchymal-like property that may be more in-
vasive and metastatic [12, 30]. Taken together, we hy-
pothesized that the TAMs are closely correlated with
EMT and may be important for cancer invasion and me-
tastasis. This hypothesis was warranted for the further
investigation.
To investigate whether the TAMs are involved in EMT,
we detected the expression of E-cadherin and vimentin in
OSCC patient samples. In contrast to our previous stud-
ies, the absence or reduced expression of E-cadherin was
not significantly associated with the clinical variables [13].
The reason for the contradictory results may be due to
the small sample size. However, the increased expression
of vimentin in OSCC was significantly associated with
lymph node metastasis, clinical stage, pathological grade,
recurrence and overall survival. Also our data suggest the
expression of CD163 in tumor cells was significantly cor-
related with the expression of E-cadherin and vimentin.
Such novel results are supported by a previous study that
CD163 expressing tumor cells may establish a subpopula-
tion of tumor cells, which could exhibit an EMT-correlated
phenotypic shift and increased metastatic ability induced by
TAMs [31]. This may extend the explanation for the
contradictory conclusions of E-cadherin in the present
study. However, in order to investigate the interaction be-
tween TAMs and cancer cells with EMT in OSCC, we
further established the TAMs in vitro and collected the CM
from TAMs for the followed study. The incubation of
TAMs CM resulted in a fibroblast-like appearance of
cancer cells (HN4, HN6 and SCC9) together with the
decreased/increased expression of E-cadherin/vimentin,
which consistent with the findings suggest that TAMs
are related with EMT transdifferentiation program in
cancer cells by showing that downregulation of E-
cadherin expression and acquisition of mesenchymal
characteristics [31–33]. It has been reported that the
cancer cells undergoing EMT was always accompanied by
an increasing in cell motility and metastasis [14, 15]. Our
results demonstrated that HN4-M, HN6-M and SCC9-M
cells could migrate into the scratched area easily, the cells
become more motile and correlated with metastasis. Fur-
thermore, the cells underwent EMT also acquired high in-
vasive ability. These findings, together with the analysis of
clinical samples, provide an extend explanation that the
TAMs could induce the EMT of cancer cells, which loss
epithelial feature, present mesenchymal phenotype and ac-
quire increase invasion and metastatic properties.
Conclusions
In conclusion, this is the novel study shows macrophage
traits and clinical significance in OSCC. The expression
of CD68 and CD163 were not only confined to the
Fig. 9 TAMs enhance the cancer cells migration and invasion in vitro. a The HN4-M, HN6-M and SCC9-M cells could grow to confluency easier
than the control cells after 24 h. b The cells invading the filters coated with the Matrigel. The photographs were taken at 100x magnification.
(c) The quantification of the cell invasion in five randomly chosen fields. The data were reported as mean ± SD. *** P < 0.001
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infiltrating TAMs, but also presented in cancer cells.
Furthermore, the expression of CD163 both in macro-
phages and in cancer cells is associated with poor overall
survival and has a significant prognostic impact in oral
cancer. Importantly, the cancer cells express CD163 has
a significant relationship with E-cadherin and vimentin
expression, which indicate TAMs are involved in the
EMT, and further studies are essential to elucidate that
the TAMs could induce the oral cancer cells undergo
EMT and show highly invasive and metastatic behavior.
Our study underlines the importance of the mutual inter-
action between the TAMs and cancer cells undergoing
EMT in tumor progression.
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